Project Optimus Elicits the "Holistic" Benefits of PK/PD Modeling of Immunotherapy.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 38743418.
- Also identified by DOI 10.1158/1078-0432.CCR-24-0553.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Leveraging a heterogeneous dataset, a recent article demonstrated the application of pharmacometric modeling to inform the dosing of nivolumab-relatlimab fixed-dose combination in special populations, including adolescents lacking clinical data. The use of model-informed approaches during clinical drug development can be cost-effective, which ensures fast access to drugs and enhances patient outcomes. See related article by Zhao et al., p. 3050.
Medical subject headings
- Immunotherapy